Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 12/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.40 |
| ▸ | MICA | Q29983 | 2/20 | 0.40 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038506 | 0.86 | SLC6A9 (0.46) | SLC6A9SLC6A5 | |
| SCHEMBL3037837 | 0.85 | SLC6A9 (0.47) | SLC6A9SLC6A5 | |
| SCHEMBL31676491 | 0.84 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL3230781 | 0.84 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL13780494 | 0.84 | SLC6A9 (0.59) | SLC6A9SLC6A5 | |
| SCHEMBL3030343 | 0.84 | SLC6A9 (0.46) | SLC6A2SLC6A4SLC6A9SLC6A5TP53 | |
| SCHEMBL3242349 | 0.83 | SLC6A9 (0.48) | SLC6A9SLC6A5 | |
| SCHEMBL3044646 | 0.82 | SLC6A9 (0.44) | SLC6A9SLC6A5 | |
| SCHEMBL3034261 | 0.82 | SLC6A9 (0.44) | SLC6A2SLC6A4SLC6A9SLC6A5POLB | |
| SCHEMBL3237991 | 0.81 | SLC6A9 (0.40) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A2 4/4885SLC6A4 9/4885SLC6A9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.